The Ministry of Health and Human Services (MoHHS) in the Turks and Caicos Islands has been testing medicines through the Caribbean Public Health Agency's post-market surveillance programme since 2021, and 20 of the 21 samples submitted — 95% — met required standards. The ministry says the results reflect the quality of medicines entering the TCI market.
The TCI's national pharmacovigilance programme, the Turks and Caicos Islands Pharmacovigilance Programme (TPP), began in 2019 under the National Pharmaceutical Policy. In 2021 the ministry partnered with the Caribbean Public Health Agency Medicines Quality Control and Surveillance Department (CARPHA MQCSD), submitting its first sample for testing on July 29, 2021 and receiving its first certificate of analysis on November 11, 2021. Samples include antihypertensives, an antidiabetic, an analgesic and a corticosteroid, rising from 2 samples in 2021 to 15 in 2025. The ministry has issued media releases to raise awareness, and growing adverse drug reaction reports show the programme gaining traction.
The MoHHS uses an Adverse Drug Reaction Reporting Form to gather reports of suspected reactions and substandard or falsified medicines, guiding which medicines warrant testing, and remains committed to building the legislative framework to keep medicine testing permanent for residents.